Federal authorities have brought down a pawn but are still looking for the king of an extensive Chinese drug counterfeiting operation who slipped through their fingers last year.
Having reached near capacity at its Ohm plant in New Jersey, much of Ranbaxy Laboratories' future production for the U.S. and Europe will come from its plant in Mohali, India.
For years now, statins, the cholesterol-lowering drugs, have been a major pillar of the drug industry. But a little cloud is forming over the category. Links to muscle injury were already documented, and now there is a growing body of evidence tying their use to the development of diabetes.
Pfizer posted higher profits for the second quarter. That's the good news. The not-so-good is that sales dropped by 9%, thanks to increased competition for the newly off-patent Lipitor. The increase in profits came on the back of cost cuts across the company, including big reductions in R&D.
AstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage.
Leave it to a patent expiration to trigger musical chairs at the top of pharma sales rankings. Plavix is now the biggest-selling drug in the U.S., after stealing the crown from Pfizer's newly off-patent Lipitor, PM Live reports.
Ranbaxy Laboratories, which is operating under an extensive consent decree with U.S. regulators, has now run afoul of authorities in India.
The generic onslaught on Pfizer's blockbuster Lipitor started just 6 months ago, but the pain is reaching Ireland where the company is poised to cut nearly 200 manufacturing jobs.
Teva Pharmaceutical Industries won't be joining the throng of genericsmakers are preparing to flood the market with copycat Lipitor.
The Indian generics company is bringing in a couple of hired guns to tell it what improvements are left to be made.